A Phase 1/2 Study of ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab

Trial Profile

A Phase 1/2 Study of ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs ALT 803 (Primary) ; Rituximab
  • Indications B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Dec 2015 Planned number of patients changed from 75 to 86 as reported by ClinicalTrials.gov record..
    • 06 Oct 2015 According to Altor Bioscience Corporation media release, the company has been awarded a grant by National Cancer Institute to support this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top